Passage Bio, Inc. (NASDAQ:PASG) Q4 2021 Earnings Conference Call March 3, 2022 8:30 AM ET Company Participants Stuart Henderson - VP, IR and Strategic Finance Bruce Goldsmith - President and CEO Eliseo Salinas - Chief Research and Development Officer Simona King - CFO Conference Call Participants Tessa Romero - J.P. Morgan Securities Omari Baruti - Goldman Sachs Neena Bitritto-Garg - Citi Yaron Werber - Cowen Debjit Chattopadhyay - Guggenheim Securities Laura Chico - Wedbush Securities Danielle Brill - Raym ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39231 PASSAGE BIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 82-2729751 (State or other ...

| --- | --- | --- | --- | |---------------------------------------------------------------|-------|-------|----------------------------------------------| | | | | | | | | | PBGM01 Study in Infantile GM1 Gangliosidosis | | | | | | | Interim Safety, Biomarker and Efficacy Results from Low Dose, | | | | | | | | | | Late Infantile Cohort of Ongoing Imagine-1 Clinical Study | | | | | | | | | | | | | | | February 11, 2022 | | | | | | | | | | | | | | | | | | | 2 Welcome & Agenda Bruce Goldsmith, Ph.D. Chief Execut ...

J.P. Morgan 40th Annual Healthcare Conference Bruce Goldsmith, Ph.D. President and Chief Executive Officer January 10, 2022 2 Forward-Looking Statement This presentation includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our planned initiation of clinical trials and the availability o ...

Passage Bio, Inc. (NASDAQ:PASG) Q3 2021 Results Conference Call November 4, 2021 8:30 AM ET Company Participants Stuart Henderson - VP, IR and Strategic Finance Bruce Goldsmith - President and CEO Eliseo Salinas - Chief Research and Development Officer Simona King - CFO Conference Call Participants Tessa Romero - JP Morgan Neena Bitritto-Garg - Citi Laura Chico - Wedbush Yun Zhong - BTIG Danielle Brill - Raymond James Brendan Smith - Cowen Operator Good morning, and welcome to the Passage Bio Third Quarter ...

Fulfilling the Promise of Genetic Medicines for Central Nervous System Disorders Corporate Presentation November 2021 NASDAQ GS: PASG 2 Forward-Looking Statement This presentation includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our planned initiation of clinical trials and the avai ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39231 PASSAGE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Fulfilling the Promise of Genetic Medicines for Central Nervous System Disorders Corporate Presentation October 2021 NASDAQ GS: PASG 2 Forward-Looking Statement This presentation includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our planned initiation of clinical trials and the avail ...

Passage Bio, Inc. (NASDAQ:PASG) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Stuart Henderson - Vice President of Investor Relations and Strategic Finance Bruce Goldsmith - President and Chief Executive Officer Eliseo Salinas - Chief Research & Development Officer Conference Call Participants Tessa Romero - JPMorgan Neena Bitritto-Garg - Citi Brendan Smith - Cowen and Company Debjit Chattopadhyay - Guggenheim Securities Laura Chico - Wedbush Securities Danielle Brill - Ray ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39231 PASSAGE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2 ...